NEW YORK (GenomeWeb News) – Immucor announced after the close of the market Tuesday that a US Food and Drug Administration committee has recommended that its platform for human erythrocyte antigen typing be cleared for clinical use.

The FDA's Blood Products Advisory Committee decided that Immucor's HEA Molecular BeadChip is "safe and effective" for typing HEA phenotypes in 35 blood group systems, the Norcross, Ga.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.